Leukemia and Lymphoma

News

Interruptions of Ibrutinib Lead to Worse Outcomes in Patients With CLL

March 27, 2020

FDA Grants Orphan Drug Status to Umbralisib for Treatment of Follicular Lymphoma

March 20, 2020 – Matthew Gavidia

Immunotherapy and AML Remains a Thorny Challenge

March 14, 2020 – Jared Kaltwasser

New Study Offers First Direct Comparison Between Venetoclax, Ibrutinib in CLL

March 09, 2020 – Jared Kaltwasser

Journals

Cost-effectiveness of Brentuximab Vedotin With Chemotherapy in Treatment of CD30-Expressing PTCL

February 11, 2020 – Tatyana Feldman, MD; Denise Zou, MA; Mayvis Rebeira, PhD; Joseph Lee, PhD; Michelle Fanale, MD; Thomas Manley, MD; Shangbang Rao, PhD; Joseph Feliciano, PharmD; Mack Harris, BA; and Anuraag Kansal, PhD

AJMCtv Interviews: ASH19 Edition

January 22, 2020 – Produced by Laura Joszt and Matthew Gavidia

ASH 2019 Interview: Data Show Fixed-Dose Daunorubicin Plus Cytarabine Leads to Fewer Inpatient Days for Patients With sAML

January 21, 2020 – Mary Caffrey

Information from Industry

Complete and Sustained BTK Inhibition With Zanubrutinib

Conferences

Patient Care Must Be an Ongoing Collaboration That Includes Multifaceted Concerns, Panel Says

March 08, 2020 – Maggie L. Shaw

Venetoclax–Obinutuzumab Demonstrates Efficacy Over Chlorambucil Combo in Untreated CLL

June 04, 2019 – Jaime Rosenberg

Dr Irene Roberts on Increased Risk of Leukemia in Patients With Down Syndrome

December 03, 2018

Multimedia

Dr Karl Kilgore Outlines Challenges of Collecting Real-World Data on CAR T-Cell Therapy

Dr Karl Kilgore Discusses Benefits of CAR T-Cell Therapy for Medicare Patients

Leukemia and Lymphoma

News

Journals

Information from Industry

Conferences

Multimedia

Sign In